Portal de investigación
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Balana, C
- Estival, A
- Teruel, I
- Hardy-Werbin, M
- Sepulveda, J
- Pineda, E
- Martinez-Garcia, M
- Gallego, O
- Luque, R
- Gil-Gil, M
- Mesia, C
- Del Barco, S
- Herrero, A
- Berrocal, A
- Perez-Segura, P
- De las Penas, R
- Marruecos, J
- Fuentes, R
- Velarde, JM
- Cardona, A
- Verger, E
- Panciroli, C
- Villa, S
Grupos
Abstract
PurposeWe retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected glioblastoma patients.Patients and methodsWe compared OS in 119 patients receiving neoadjuvant therapy followed by standard treatment (NA group) and 96 patients receiving standard treatment without neoadjuvant therapy (NoNA group). The MaxStat package of R identified the optimal cut-off point for waiting time to radiotherapy.ResultsOS was similar in the NA and NoNA groups. Median waiting time to radiotherapy after surgery was 13weeks for the NA group and 4.2weeks for the NoNA group. The longest OS was attained by patients who started radiotherapy after 12weeks and the shortest by patients who started radiotherapy within 4weeks (12.3 vs 6.6months) (P=0.05). OS was 6.6months for patients who started radiotherapy before the optimal cutoff of 6.43weeks and 19.1months for those who started after this time (P=0.005). Patients who completed radiotherapy had longer OS than those who did not, in all 215 patients and in the NA and NoNA groups (P=0.000). In several multivariate analyses, completing radiotherapy was a universally favorable prognostic factor, while neoadjuvant therapy was never identified as a negative prognostic factor.ConclusionIn our series of unresected patients receiving neoadjuvant treatment, in spite of the delay in starting radiotherapy, OS was not inferior to that of a similar group of patients with no delay in starting radiotherapy.
Datos de la publicación
- ISSN/ISSNe:
- 1699-048X, 1699-3055
- Tipo:
- Article
- Páginas:
- 1529-1537
- Factor de Impacto:
- 0,883 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico SPRINGER-VERLAG ITALIA SRL
Documentos
- No hay documentos
Filiaciones
Keywords
- Glioblastoma; Neoadjuvant; Unresected; Radiotherapy delay; MGMT; Prognosis; Glioblastoma; Neoadjuvant therapy; Waiting time to radiotherapy; Overall survival
Proyectos asociados
ESTUDIO RETROSPECTIVO DEL MANEJO DE PACIENTES CON CANCER DE PROSTATA HORMONORESISTENTE AVANZADO. ESTUDIO ESPRO.
Investigador Principal: GASPAR REYNES MUNTANER
SAN-DOC-2010-02 . 2011
ENSAYO CLÍNICO FASE II PILOTO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE PF299804, UN INHIBIDOR PAN-HER IRREVERSIBLE, EN PACIENTES CON GLIOBLASTOMA RECURRENTE CON AMPLIFICACIÓN DE EGFR O PRESENCIA DE LA MUTACIÓN EGFRVIII .
Investigador Principal: GASPAR REYNES MUNTANER
GEINO-11 . 2012
ENSAYO CLINICO, FASE II ALEATORIZADO DE TRATAMIENTO NEO-ADYUVANTE CON DOS CICLOS DE TEMOZOLOMIDA A DOSIS EXTENDIDAS, PREVIOS AL TRATAMIENTO CON TEMOZOLOMIDA MAS IRRADIACION Y POSTERIOR ADYUVANCIA CON TEMOZOLOMIDA VERSUS MISMO TRATAMIENTO CON BEVACIZUMAB
Investigador Principal: GASPAR REYNES MUNTANER
GENOM-009 . 2010
Cita
Balana C,Estival A,Teruel I,Hardy M,Sepulveda J,Pineda E,Martinez M,Gallego O,Luque R,Gil M,Mesia C,Del Barco S,Herrero A,Berrocal A,Perez P,De las Penas R,Marruecos J,Fuentes R,Reynes G,Velarde JM,Cardona A,Verger E,Panciroli C,Villa S. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. Clin Transl Oncol. 2018. 20. (12):p. 1529-1537. IF:2,441. (3).